(Invitrogen). FITC-coupled antibodies were amplified with goat anti-FITC IgG-Alexa 488 (Molecular Probes). Secondary antibodies used were: F(ab')2 goat anti-mouse Alexa 594, F(ab')2 goat anti-mouse Alexa 488, F(ab')2 goat anti-rabbit Alexa 594, F(ab')2 goat anti-rabbit Alexa 488, donkey anti-goat Alexa 594, and donkey anti-goat Alexa 488, donkey anti-rat Alexa 488 (all from Molecular Probes).
Antibodies used for cytokine ELISAs were: anti-IL2 capture clone JES6-1A12, anti-IL-2 detection JES6-5H4, anti-IFN-γ capture R4-6A2, anti-IFN-γ detection clone XMG1.2 (BD Pharmingen). Antibodies used for fusion protein targeting in vivo were anti-mouse TLR2 (clone MCA2266, Serotec), anti-mouse MR (clone MCA2235, Serotec).
Microsome fractionation and IRAP purification. Identification of IRAP in crude microsomal
fractions tested for aminopeptidase activity from MGAR human B lymphoblastoid cells was performed as previously described for ERAP1/ERAP2 (4) . Mass spectrometry analysis of peak 4 resulted in identification of peptide ILEALASSEDVR derived from IRAP. All other peptides identified in peak 4 were derived either from HLA class I heavy chains or from β2m. For IFN-γ induction of aminopeptidase activities, HeLa cells were treated for 48 h with 500 U/ml human IFN-γ (TEBU-BIO). Analysis of IRAP mRNA expression by quantitative PCR was also performed as previously described for ERAP enzymes (4), using the primers: 5'-TACGTTGAAGATAGAGTACT (sense), and 5'-TCAAACTGAGTTGCTGCAAA (antisense).
Digestions. For digestions of peptide K15I, recombinant human IRAP truncated by the 130 aminoterminal amino acids, preceded by the signal peptide from the baculovirus capsid protein gp64 (6) and extended by six carboxy(C)-terminal histidine residues was expressed in baculovirus-infected Hi5 cells. Soluble IRAP was purified from insect cell supernatant by affinity chromatography using Ni-Nta-agarose beads (Invitrogen). Ten µg of peptide K15I were digested with 0.5 µg of IRAP for different periods using previously described experimental conditions (4), followed by separation of products by cation exchange chromatography.
Expression cloning.
Complementary DNA encoding murine Rab14 was PCR-amplified from BM-DCs and cloned into pEGFP-C1 (Clontech). To produce expression constructs encoding murine IRAP variants, full length or truncated IRAP cDNA was PCR-amplified with appropriate primers that added a C-terminal HA tag as well as a KDEL sequence in the case of the ER-targeted variant. All constructs were sequenced to confirm absence of PCR-induced errors and cloned into pMAX (Lonza, Cologne, Germany). DCs were transfected with expression plasmids using a Nucleofector™ equipment (Lonza) 36 h prior to microscopy analysis.
Fluorescence microscopy. Human myeloid DCs, mouse BM-DCs or splenic CD11c hi DCs purified using paramagnetic beads (Miltenyi) were seeded in IBIDI™ (Martinsried, Germany) slides and fed cross-presentable antigens for various periods. To synchronize phagosome maturation, DCs were first incubated for 10 min at 37°C with yeast cells or beads. Then cells were washed, and incubated further at 37°C until the total phagocytosis period was attained.
Cells were fixed with PFA 4% and permeabilized with saponine 0.2%, BSA 0.5% in PBS. For staining of the cell membrane, cells were incubated for 10 min at room temperature in PBS containing 1 µM CM-Dil before permeabilization. For staining of cell surface MHC class I, cells were incubated before phagocytosis with antibodies W6/32, B22 or AF6-88.5-Biotin at 4°C for 15 min. Secondary reagents were Alexa 594-labeled streptavidin or goat anti-mouse antibodies. To examine co-localization of total cellular MHC class I molecules with IRAP ( Fig.   2C ), cells were first stained with anti-MHC class I rabbit serum P8 followed by a secondary antibody. Then cells were blocked for 1 h with non-immune rabbit serum, and finally stained with rabbit anti-IRAP antibodies labeled with Alexa 594 using a Zenon anti-rabbit kit (Molecular Probes). Images were acquired on a Leica DMI 6000 microscope equipped with a piezoelectric-driven stage and Optophotonics XF100-2 (FITC), XF102-2 (Texas Red) and XF06 (DAPI) filters, and processed for 3D deconvolution using Metamorph™ 6.3.7. When cells were co-stained using CM-Dil and Alexa 488 labeled secondary antibodies, the filter XF202 (FITC narrow) was used for detection of green fluorescence. Determination of the percentage of IRAP co-localizing with other markers was carried out using correlation maps (7) together with the Metamorph™ 6.3.7 co-localization module. We used a fixed threshold of the local correlation coefficient of 0.4 for the correlation map and a fixed threshold of 10% of the maximum grey levels for the fluorescence to be quantified. The percentage of co-localization for each protein is reported as the proportion of its fluorescence that overlays the correlation map. This percentage, calculated for at least five cells for each co-localization evaluated, was calculated using the co-localization module of MetaMorph™ 6.3.7 software. Fig. S2 shows an example of co-localization quantification.
DC culture. Mouse BM-DCs were prepared by growing BM cells for 7 days in IMDM media with 10% FCS and 20% GM-CSF supernatant from J558 cells at 0.5x10 6 cells/ml. Human DCs were grown from monocytes isolated using anti-CD14 magnetic beads (Miltenyi) and cultured for 6 days in RPMI medium supplemented with 10% human serum, 8 ng/ml human recombinant GM-CSF and 16 ng/ml human IL-4 (R&D Systems).
Immunoprecipitations and immunoblots.
To study association of IRAP and MHC class I, Antigens for MHC class I cross-presentation assays included OVA-coated latex beads, obtained by overnight incubation with 50 mg/ml OVA and washed three times in cold PBS. Additional experiments were performed with SF9 insect cells infected for 24 h with recombinant baculoviruses expressing novel fusion proteins, lysed by two freeze-thaw cycles and washed extensively. These fusion proteins consisted of (from N-to C-terminal) two or three immunoglobulin-binding protein G domains, an ubiquitin molecule, and complete OVA, or the minimal epitope S8L, or S8L preceded by the sequence Cys-Ser-Cys. Fusion proteins were used both as particulate antigens associated with necrotic cells obtained as described above, and after purification from serum-free insect cell supernatants and pre-incubation with antibodies recognizing DC surface receptors. When targeted to DC surface receptors using specific antibodies, these fusion proteins prime and stimulate CD8+ T cell responses in vitro and in vivo with an efficacy at least 100-fold superior to that of unmodified OVA.
To study the standard processing pathway for MHC class II restricted presentation of soluble exogenous proteins, we used OT-II transgenic CD4 + T cells (10) . BM-DCs were incubated for 7 h with 1 mg/ml soluble OVA or 100 nM peptide OVA323-39 (ISQAVHAAHAEINEAGR), washed and fixed before addition of OT-II effector cells. DCs were fixed in 0.002% glutaraldehyde before addition to OT-I or OT-II cells. OT-II effectors were produced by incubating splenocytes from RAG ko OT-II mice with cognate peptide-pulsed splenocytes from SV129 wt mice in a ratio of 1:1. Forty-eight h later, 10% T cell growth factor was added, and renewed every 48 h. Cells were used between day 6 and 11 after antigenic stimulation, and stimulation was assessed by measuring IL-2 secretion.
Cytochalasin D (10µM) or wortmannin (5nM) were added to the BM-DCs for 1 h before antigen addition. Protease inhibitors were used at the following concentrations unless indicated otherwise: epoxomicin, 0.2 µM; chloroquine, 25 µM; bafilomycin A1, 25 nM; MG132, 0.6 µM.
In vivo T cell proliferation assay. For adoptive transfer tests using OT-I T cells, 2x10 6 lymph node cells from RAG ko OT-I or HY mice were labeled with 10 µM CFSE. CFSE-labeled lymph node cells were injected i.v. into recipient mice, followed 24 h later by i.v. injection of antigens. Cross-presented antigens were: 0.5x10 6 β2m ko splenocytes electroporated with OVA as described (11); 10 7 male Balb/c splenocytes (for HY T cell-injected mice); or fusion protein PrG(3x)-Ub-OVA pre-incubated for 2 h at 4°C with targeting antibodies at a molar ratio of 1:1.
The amount of fusion protein per mouse was: 1 µg for targeting to the MR, 0.8 µg for TLR2
targeting. Three days after antigen injection, spleens were removed, and proliferation measured in CD8 + cells identified using Vß-or clonotype-specific antibodies, as described (11) 
